Amneal Pharmaceuticals NY LLC secured FDA approval for oral MACITENTAN on June 8, 2026, a strategic move expected to diversify the company’s portfolio and intensify competition within the oral endothelin receptor antagonist market.
Amneal Pharmaceuticals NY LLC secured FDA approval for oral MACITENTAN on June 8, 2026, a strategic move expected to diversify the company’s portfolio and intensify competition within the oral endothelin receptor antagonist market.